Production (Stage)
4D Molecular Therapeutics, Inc.
FDMT
$3.49
-$0.11-3.06%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -68.75% | -59.53% | -49.56% | 1.32% | 4.81% |
| Total Depreciation and Amortization | 15.75% | 16.63% | 14.40% | 19.97% | 31.51% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -3.08% | 2.01% | 8.13% | 8.75% | 14.08% |
| Change in Net Operating Assets | -294.50% | -14.76% | 1,354.85% | 90.02% | 148.68% |
| Cash from Operations | -99.10% | -77.57% | -54.55% | 8.64% | 15.45% |
| Capital Expenditure | -50.14% | -36.63% | -2.14% | 58.70% | 59.76% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 98.13% | -352.05% | -447.80% | -505.14% | -318.02% |
| Cash from Investing | 96.21% | -361.36% | -465.02% | -535.35% | -337.77% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -96.04% | 115.04% | 120.86% | 142.53% | 3,281.13% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 183.36% | 123.71% |
| Cash from Financing | -96.04% | 115.04% | 121.53% | 144.00% | 3,354.80% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -172.11% | -150.71% | -152.66% | -138.47% | 7,480.80% |